Lumateperone-13C,d3 (tosylate)

Lumateperone-13C,d3 (tosylate)

• UNSPSC Description: Lumateperone-13C,d3 (ITI-007-13C,d3) tosylate is 13C and deuterium labeled Lumateperone (tosylate). Lumateperone (ITI-007) tosylate is a 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a dopamine D1 receptor modulator. Lumateperone tosylate has anticancer activity and can also be used in studies of psychiatric disorders such as schizophrenia[1][2][3][4].
• Target Antigen: 5-HT Receptor; Dopamine Receptor; Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: GPCR/G Protein;Neuronal Signaling;Others
• Field of Research: Neurological Disease;Cancer
• Smiles: O=C(CCCN1C[C@@]([H])(C2=CC=CC3=C2N4CCN3[13C]([2H])([2H])[2H])[C@]4([H])CC1)C5=CC=C(F)C=C5.CC6=CC=C(C=C6)S(O)(=O)=O
• Molecular Weight: 569.71
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]Lumateperone|[3]Jinyuan Zhang, et al. Identification of Trovafloxacin, Ozanimod, and Ozenoxacin as Potent c-Myc G-quadruplex Stabilizers to Suppress c-Myc Transcription and Myeloma Growth. Mol Inform. 2022 Mar 30:e2200011.|[4] J Titulaer, et al. Lumateperone-mediated effects on prefrontal glutamatergic receptor-mediated neurotransmission: A dopamine D1 receptor dependent mechanism. Eur Neuropsychopharmacol. 2022 Jul 22;62:22-35.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported